|本期目录/Table of Contents|

[1]王雪清,马一弌,刘颖,等.pH敏感黄芩苷脂质体的制备及其口腔抗炎评价[J].天津医科大学学报,2025,31(05):435-440.[doi:10.20135/j.issn.1006-8147.2025.05.0435]
　WANG Xueqing,MA Yiyi,LIU Ying,et al.Preparation of pH sensitive baicalin liposomes and evaluation of oral anti-inflammatory effects[J].Journal of Tianjin Medical University,2025,31(05):435-440.[doi:10.20135/j.issn.1006-8147.2025.05.0435]
点击复制

pH敏感黄芩苷脂质体的制备及其口腔抗炎评价(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
31卷
期数:
2025年05期
页码:
435-440
栏目:
基础医学
出版日期:
2025-09-20

文章信息/Info

Title:
Preparation of pH sensitive baicalin liposomes and evaluation of oral anti-inflammatory effects
文章编号:
1006-8147(2025)05-0435-06
作者:
王雪清1; 马一弌2; 刘颖2; 吴伯岳2; 朱彧1
1.天津医科大学三中心临床学院，天津300170；2.天津医科大学医学技术学院生物化学系，天津300203
Author(s):
WANG Xueqing1;  MA Yiyi2;  LIU Ying2;  WU Boyue2;  ZHU Yu1
1. The Third Central Clinical College of Tianjin Medical University，Tianjin 300170，China；2. Department of Biochemistry，College of Medical Technology，Tianjin Medical University，Tianjin 300203，China
关键词:
黄芩苷; pH敏感脂质体; 抗炎; 牙周炎
Keywords:
baicalin;  pH-sensitive liposomes;  anti-inflammatory;  periodontitis
分类号:
R932
DOI:
10.20135/j.issn.1006-8147.2025.05.0435
文献标志码:
A
摘要:
目的：制备pH敏感的黄芩苷脂质体（pH-Bai-Lips），探讨其体外抗炎效果。方法：采用薄膜分散法制备pH-Bai-Lips混悬液后，首先系统性考察脂质体的形貌、粒径、包封率（EE）、载药率（LE）、酸响应性以及体外释放率等关键理化性质。在完成基础理化表征的基础上，采用MTT法检测pH-Bai-Lips对RAW264.7细胞24 h活力的影响，评估其体外生物安全性。基于安全性验证结果，进一步通过脂多糖（LPS）刺激RAW264.7细胞构建炎症模型，运用流式细胞术定量分析pH-Bai-Lips对促炎因子[肿瘤坏死因子-α（TNF-α）、白细胞介素（IL）-6]和抗炎因子（IL-10）表达的调控作用。结果：结果显示，脂质体在电镜下呈类圆形，平均粒径为（220.0±2.6） nm，EE为94.94%，LE为26.37%。MTT实验结果显示，pH-Bai-Lips在1~100 μg/mL浓度梯度处理RAW264.7细胞时，各浓度组与对照组相比细胞活力差异无统计学意义（t=0.25、0.29、0.26，均P>0.05）。抗炎结果显示，在LPS诱导的RAW264.7细胞炎症模型中，与LPS组相比，1 μg/mL pH-Bai-Lips组、10 μg/mL pH-Bai-Lips组和100 μg/mL pH-Bai-Lips组可呈浓度依赖性降低促炎因子IL-6（t=11.78、22.47、21.37，均P<0.001）、TNF-α水平（t=7.76、23.28、23.41，均P<0.001）；同时升高抗炎因子IL-10水平（t=7.65、20.35、6.45，均P<0.001）。结论：采用薄膜分散法制备的pH-Bai-Lips具有良好的生物安全性和体外细胞抗炎效果。
Abstract:
Objective： To prepare of pH sensitive baicalin liposomes（pH-Bai-Lips） and investigate their anti-inflammatory effects in vitro. Methods： pH-Bai-Lips suspension was prepared using the thin-film dispersion method. The key physicochemical properties of the liposomes including morphology， particle size， encapsulation efficiency（EE）， drug loading capacity（LE）， pH respo-nsiveness， and release rate in vitro were systematically characterized. Following basic physicochemical characterization， biological safety in vitro of pH-Bai-Lips was assessed via MTT assay by measuring its impact on RAW264.7 cell viability after 24 h exposure. Based on the safety validation results， an inflammatory model was further established using lipopolysaccharides （LPS）-stimulated RAW264.7 cells. Flow cytometry was employed to quantitatively analyze the regulatory effects of pH-Bai-Lips on the expression of pro-inflammatory cyto-kines （TNF-α， IL-6） and the anti-inflammatory cytokine（IL-10）. Results： The study demonstrated that the liposomes exhibited a spherical morphology under electron microscopy， with an average particle size of （220.0 ± 2.6） nm， an EE of 94.94%， and a LE of 26.37%. In the MTT assay， RAW264.7 cells treated with pH-Bai-Lips at concentrations ranging from 1 to 100 μg/mL showed no statistically significant differences in cell viability compared with the control group （t=0.25， 0.29， 0.26， all P>0.05）. These results indicated that pH-Bai-Lips did not exhibit significant cytotoxicity within this concentration range. The anti-inflammatory results showed that in the LPS-induced RAW264.7 cell inflammation model， compared with the LPS group， pH-Bai-Lips treatment at concentrations of 1， 10， and 100 μg/mL significantly and dose-dependently reduced pro-inflammatory cytokine IL-6 levels（t=11.78， 22.47， 21.37， all P<0.001） and TNF-α levels （t=7.76， 23.28， 23.41， all P<0.001）. Meanwhile， the treatment significantly increased the anti-inflammatory cytokine IL-10 level （t=7.65， 20.35， 6.45， all P<0.001）. Conclusion： pH-Bai-Lips prepared by film dispersion method have good biological safety and cellular anti-inflammatory effects in vitro.

参考文献/References:

[1] WEI Y， LIANG J， ZHENG X， et al. Lung-targeting drug delivery system of baicalin-loaded nanoliposomes： development， biodistribution in rabbits， and pharmacodynamics in nude mice bearing orthotopic human lung cancer[J]. Int J Nanomed， 2017， 12（8）： 251-261.
[2] GENG P， ZHU H， ZHOU W， et al. Baicalin inhibits influenza a virus infection via promotion of M1 macrophage polarization[J]. Front Pharmacol， 2020， 11（7）： 01298.
[3] CHEN Y， MINH L V， LIU J， et al. Baicalin loaded in folate-PEG modified liposomes for enhanced stability and tumor targeting[J]. Colloids Surf B， 2016， 140（28）： 74-82.
[4] ZHANG P， HOU J， FU J， et al. Baicalin protects rat brain microvascular endothelial cells injured by oxygen-glucose deprivation via anti-inflammation[J]. Brain Res Bull， 2013， 97（4）： 8-15.
[5] XU M， CHEN X， GU Y， et al. Baicalin can scavenge peroxynitrite and ameliorate endogenous peroxynitrite-mediated neurotoxicity in cerebral ischemia-reperfusion injury[J]. J Ethnopharmacol， 2013， 150（1）： 116-124.
[6] FU Y J， XU B， HUANG S W， et al. Baicalin prevents LPS-induced activation of TLR4/NF-κB p65 pathway and inflammation in mice via inhibiting the expression of CD14[J]. Acta Pharmacol Sin， 2021， 42（1）： 88-96.
[7] AN H J， LEE J Y， PARK W. Baicalin modulates inflammatory response of macrophages activated by LPS via Calcium-CHOP pathway[J]. Cells， 2022， 11（19）： 3076.
[8] XIANG Y， LONG Y， YANG Q， et al. Pharmacokinetics， pharmacodynamics and toxicity of Baicalin liposome on cerebral ischemia reperfusion injury rats via intranasal administration[J]. Brain Res， 2020， 1726（14）： 146503.
[9] XING J， CHEN X， ZHONG D. Absorption and enterohepatic circulation of baicalin in rats[J]. Life Sci， 2005， 78（2）： 140-146.
[10] ZHANG S， WANG J， PAN J. Baicalin-loaded PEGylated lipid nanoparticles： characterization， pharmacokinetics， and protective effects on acute myocardial ischemia in rats[J]. Drug Deliv， 2016， 23（9）： 3696-3703.
[11] LI N， FENG L， TAN Y， et al. Preparation， characterization， pharmacokinetics and biodistribution of baicalin-loaded liposome on cerebral ischemia-reperfusion after i.v. administration in rats[J]. Molecules， 2018， 23（7）： 1747-1750.
[12] SLEPUSHKIN V A， SIM?簟ES S， DAZIN P， et al. Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo[J]. J Biol Chem， 1997， 272（4）： 2382-2388.
[13] YANAR F， KIMPTON H， CRISTALDI D A， et al. Synthesis and characterization of liposomes encapsulating silver nanoprisms obtained by millifluidic-based production for drug delivery[J]. Mater Res Express， 2023， 10（8）： 085008.
[14] JASIM A J， ALBUKHATY S， SULAIMAN G M， et al. Liposome nanocarriers based on γ oryzanol： preparation， characterization， and in vivo assessment of toxicity and antioxidant activity[J]. ACS omega， 2024， 9（3）： 3554-3564.
[15] ETTOUMI F E， ZHANG R， XU Y， et al. Synthesis and characterization of fucoidan/chitosan-coated nanoliposomes for enhanced stability and oral bioavailability of hydrophilic catechin and hydrophobic juglone[J]. Food Chem， 2023， 423（16）： 136330.
[16] SOLOMON D， GUPTA N， MULLA N S， et al. Role of in vitro release methods in liposomal formulation development： challenges and regulatory perspective[J]. AAPS J， 2017， 19（6）： 1669-1681.
[17] SONG Z， YIN J， XIAO P， et al. Improving breviscapine oral bioavailability by preparing nanosuspensions， liposomes and phospholipid complexes[J]. Pharmaceutics， 2021， 13（2）： 132.
[18] JIN X， LIU M Y， ZHANG D F， et al. Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4/NF-κB signaling pathway[J]. Cns Neurosci Ther， 2019， 25（5）： 575-590.
[19] LI Y， LIU T， LI Y， et al. Baicalin ameliorates cognitive impairment and protects microglia from LPS-induced neuroinflammation via the SIRT1/HMGB1 pathway[J]. Oxid Med Cell Longev， 2020， 2020（9）： 4751349.
[20] LI C G， YAN L， MAI F Y， et al. Baicalin inhibits NOD-Like receptor family， pyrin containing domain 3 inflammasome activation in murine macrophages by augmenting protein kinase a signaling[J]. Front Immunol， 2017， 8（5）： 1409-1411.
[21] SIM?ES S， MOREIRA J N， FONSECA C， et al. On the formulation of pH-sensitive liposomes with long circulation times[J]. Adv Drug Deliver Rev， 2004， 56（7）： 947-965.
[22] KRAFT J C， FREELING J P， WANG Z， et al. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems[J]. J Pharm Sci， 2014， 103（1）： 29-52.
[23] LI M， HUANG X， ZHUO Q， et al. Clinical significance of miR-129-5p in patients with neonatal sepsis and its regulatory role in the LPS-induced inflammatory response[J]. Bosnia J Basic Med， 2021， 22（2）： 185-190.
[24] KASRAIE S， WERFEL T. Role of macrophages in the pathogenesis of atopic dermatitis[J]. Mediat Inflamm， 2013， 2013（4）： 942375.
[25] KELLY C， JEFFERIES C， CRYAN S A. Targeted liposomal drug deliveryto monocytes and macrophages[J]. J Drug Deliv Sci Tec， 2011， 2011（5）： 727241.
[26] OZMA M A， KHODADADI E， PAKDEL F， et al. Baicalin， a natural antimicrobial and anti-biofilm agent[J]. JHM， 2021， 27（7）： 105-109.
[27] JEONG G H， LEE H， LEE H K， et al. Inhibitory effect of gamma-ray-modified hydroxymethylated baicalins on NO production[J]. Bioorg Med Chem Lett， 2023， 96（3）： 129491.
[28] ZHANG Q， GUO S， GE H， et al. The protective role of baicalin regulation of autophagy in cancers[J]. Cytotechnology， 2025， 77（1）： 33.

相似文献/References:

备注/Memo

备注/Memo:
基金项目:天津市中医药重点领域科研项目（2022008）
作者简介:王雪清（1997-），女，硕士在读，研究方向：医学检验技术；通信作者：朱彧，E-mail：zhuyutj@126.com。
更新日期/Last Update: 2025-10-01